Since its introduction to the clinic, L-asparaginase proved remarkably effective with 93% complete remission in pediatric patients diagnosed with ALL.5 Part of this improved treatment was brought about by the use of chemically modified form of L-asparaginase covalently conjugated to polyethylene glycol to decrease immunogenicity of the enzyme and prolong its half-life.6,7. Here, ASPG is linked to acute lymphoblastic leukemia.